ARWR

14.71

12.23% -2.05

Handel nachbörslich: 14.85 0.14 +0.95%

Arrowhead Pharmaceuticals Inc (ARWR)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt ARWR? Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$16.76

Offen:

$16.96

24-Stunden-Volumen:

6.75M

Relative Volume:

3.80

Marktkapitalisierung:

$2.03B

Einnahmen:

$181.74M

Nettoeinkommen (Verlust:

$-143.97M

KGV:

-10.58

EPS:

-1.39

Netto-Cashflow:

$9.60M

1W Leistung:

-20.96%

1M Leistung:

-3.98%

6M Leistung:

-25.56%

1J Leistung:

-48.02%

1-Tages-Spanne:

$14.32

$17.00

1-Wochen-Bereich:

$14.32

$19.32

52-Wochen-Spanne:

$9.57

$29.86

Arrowhead Pharmaceuticals Inc Stock (ARWR) Company Profile

Firmenname

Arrowhead Pharmaceuticals Inc

Sektor

Healthcare (1161)

Branche

Biotechnology (654)

Telefon

626-696-4702

Adresse

177 E COLORADO BLVD, PASADENA, CA

Mitarbeiter

609

Twitter

@ArrowheadPharma

Nächster Verdiensttermin

2025-02-10

Neueste SEC-Einreichungen

ARWR's Discussions on Twitter

Vergleichen Sie ARWR mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ARWR Arrowhead Pharmaceuticals Inc	14.71	2.57B	181.74M	-143.97M	9.60M	-1.39
VRTX Vertex Pharmaceuticals Inc	458.49	121.30B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	545.53	61.60B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	320.52	41.17B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	566.14	34.35B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	291.93	27.29B	3.81B	-644.79M	-669.77M	-6.24

Arrowhead Pharmaceuticals Inc Stock (ARWR) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-06-05	Eingeleitet	Goldman	Neutral
2023-12-04	Eingeleitet	BofA Securities	Buy
2023-09-19	Eingeleitet	Citigroup	Neutral
2023-07-21	Eingeleitet	TD Cowen	Outperform
2023-05-12	Herabstufung	SVB Securities	Outperform → Market Perform
2023-04-26	Eingeleitet	SMBC Nikko	Outperform
2023-04-12	Hochstufung	SVB Securities	Market Perform → Outperform
2023-03-21	Eingeleitet	Bernstein	Mkt Perform
2022-09-09	Eingeleitet	Morgan Stanley	Equal-Weight
2022-05-11	Hochstufung	Robert W. Baird	Neutral → Outperform
2022-01-19	Fortgesetzt	Goldman	Buy
2021-08-06	Bestätigt	Chardan Capital Markets	Buy
2021-06-04	Fortgesetzt	Robert W. Baird	Neutral
2021-02-05	Bestätigt	H.C. Wainwright	Buy
2020-12-21	Herabstufung	Robert W. Baird	Outperform → Neutral
2020-12-16	Eingeleitet	UBS	Buy
2020-11-19	Eingeleitet	Citigroup	Buy
2020-05-13	Eingeleitet	RBC Capital Mkts	Outperform
2020-05-08	Hochstufung	Oppenheimer	Perform → Outperform
2020-04-15	Hochstufung	Cantor Fitzgerald	Neutral → Overweight
2020-03-24	Hochstufung	SVB Leerink	Underperform → Mkt Perform
2020-03-17	Eingeleitet	Goldman	Neutral
2020-01-21	Eingeleitet	SVB Leerink	Underperform
2019-12-13	Eingeleitet	Oppenheimer	Perform
2019-11-29	Bestätigt	Chardan Capital Markets	Buy
2019-11-27	Bestätigt	B. Riley FBR	Buy
2019-11-25	Hochstufung	Robert W. Baird	Neutral → Outperform
2019-10-24	Herabstufung	Robert W. Baird	Outperform → Neutral
2019-10-22	Bestätigt	Chardan Capital Markets	Buy
2019-10-03	Eingeleitet	Robert W. Baird	Outperform
2018-09-07	Hochstufung	B. Riley FBR	Neutral → Buy
2018-09-06	Bestätigt	Chardan Capital Markets	Buy
2018-08-08	Bestätigt	Cantor Fitzgerald	Overweight
2018-07-02	Bestätigt	Chardan Capital Markets	Buy

Alle ansehen

Arrowhead Pharmaceuticals Inc Aktie (ARWR) Neueste Nachrichten

04:01 AM

Arrowhead Pharmaceuticals Sets Q3 Earnings Date: What Biotech Investors Should Mark on Their Calendar - Stock Titan

04:01 AM

11:58 AM

Arrowhead hits the skids due to partnership with Sarepta - Seeking Alpha

11:58 AM

10:35 AM

Arrowhead Pharmaceuticals Plummets 9.4%: A Bearish Surprise in Biotech's RNAi Frontier - AInvest

10:35 AM

12:10 PM

What analysts say about Arrowhead Pharmaceuticals Inc. stockConsistent triple-digit returns - jammulinksnews.com

12:10 PM

Jul 20, 2025

Arrowhead Pharmaceuticals Inc. Stock Analysis and ForecastPowerful market insights - Autocar Professional

Jul 20, 2025

What drives Arrowhead Pharmaceuticals Inc. stock priceRapid profit acceleration - Autocar Professional

Jul 20, 2025

Jul 19, 2025

Is Arrowhead Pharmaceuticals Inc. a good long term investmentExceptional growth trajectory - jammulinksnews.com

Jul 19, 2025

Jul 18, 2025

Insiders At Arrowhead Pharmaceuticals Sold US$3.1m In Stock, Alluding To Potential Weakness - simplywall.st

Jul 18, 2025

Jul 10, 2025

Arrowhead Pharmaceuticals Advances Phase 3 Study on Plozasiran for Hypertriglyceridemia - TipRanks

Jul 10, 2025

Jul 09, 2025

Arrowhead Pharmaceuticals (ARWR) Soars 7.64% on Clinical Trial Advances - AInvest

Jul 09, 2025

Arrowhead Pharmaceuticals Advances Phase 3 Study of Zodasiran for Cholesterol Management - TipRanks

Jul 09, 2025

Jul 08, 2025

Arrowhead Pharmaceuticals' Zodasiran: A Pioneering ANGPTL3 Inhibitor for HoFH and Beyond - AInvest

Jul 08, 2025

Arrowhead Pharmaceuticals initiates phase 3 Yosemite study of investigational zodasiran - MarketScreener

Jul 08, 2025

Arrowhead Pharmaceuticals Initiates Phase 3 YOSEMITE Study of Investigational Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia - Business Wire

Jul 08, 2025

Jun 25, 2025

Hepatitis D Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Eiger Biopharmaceuticals, Arrowhead Pharmaceuticals, Antios Therapeutics, PharmaEsse - The Globe and Mail

Jun 25, 2025

Jun 23, 2025

Arrowhead Pharmaceuticals Completes Enrollment in SHASTA-3, SHASTA-4, and MUIR-3 Phase 3 Studies of Plozasiran - Business Wire

Jun 23, 2025

Jun 12, 2025

Where are the Opportunities in (ARWR) - news.stocktradersdaily.com

Jun 12, 2025

Homozygous Familial Hypercholesterolemia Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Arrowhead Pharma, Novartis, Alnylam Pharma, LIB Therapeutics, Amryt Pharma - The Globe and Mail

Jun 12, 2025

GAMMA Investing LLC Increases Stock Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - Defense World

Jun 12, 2025

Cantor Fitzgerald Weighs in on ARWR FY2026 Earnings - Defense World

Jun 12, 2025

Jun 10, 2025

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World

Jun 10, 2025

Jun 09, 2025

Arrowhead Pharmaceuticals at Goldman Sachs Conference: Strategic Launch Plans By Investing.com - Investing.com Canada

Jun 09, 2025

Jun 08, 2025

California State Teachers Retirement System Reduces Holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - Defense World

Jun 08, 2025

Jun 07, 2025

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Upgraded to “Buy” at Wall Street Zen - Defense World

Jun 07, 2025

Jun 05, 2025

Jim Cramer on Arrowhead Pharmaceuticals (ARWR): “It Doesn’t Make Any Money” - Insider Monkey

Jun 05, 2025

Jun 04, 2025

Arrowhead at Jefferies Conference: Strategic Pipeline Insights By Investing.com - Investing.com Canada

Jun 04, 2025

Jim Cramer: Arrowhead Pharmaceuticals Doesn't 'Have The Horses' - Benzinga

Jun 04, 2025

Arrowhead Pharmaceuticals to Participate in June 2025 Investor Conferences - Business Wire

Jun 04, 2025

Jun 02, 2025

Arrowhead (ARWR) Kicks Off Clinical Trial for Obesity Treatment ARO-ALK7 | ARWR Stock News - GuruFocus

Jun 02, 2025